SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that results
from preclinical studies of its investigative drug candidate
olorinab, a peripherally restricted, highly selective, full agonist
of the cannabinoid receptor 2 (CB2) in development for
the treatment of visceral pain associated with Crohn's disease,
were presented at the International Association for the Study of
Pain (IASP) World Congress in Boston, MA.
"We are pleased to present data supporting olorinab's
antinociceptive effects in visceral sensory pathways," said
Preston Klassen, MD, MHS, Executive
Vice President, Research and Development and Chief Medical Officer
of Arena. "Through its full-agonism and selectivity, we believe
olorinab may provide a novel therapeutic approach for sustained
relief of visceral pain without psychotropic effects, potentially
providing a new treatment option without the risk for dependence or
abuse. We are currently evaluating olorinab in a Phase 2 clinical
trial in IBD-associated abdominal pain and expect the availability
of topline data by the end of the third quarter."
Presentation Details
Poster Abstract Title: APD371, a
Peripherally Restricted, Highly Selective, Full Agonist of the
Cannabinoid Receptor 2 (CB2) Receptor, Reduces Colitis-Induced
Visceral Hypersensitivity in Rats
Poster Number: PFR455
Presentation Date: Friday, September
14
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on delivering novel, transformational medicines with
optimized pharmacology and pharmacokinetics to patients globally.
Arena's proprietary pipeline includes multiple potentially first-
or best-in-class programs with broad clinical utility. The most
advanced investigational clinical programs are ralinepag (APD811),
in a Phase 3 program for pulmonary arterial hypertension (PAH), and
etrasimod (APD334), expected to commence a Phase 3 program for
ulcerative colitis (UC) and a program in Crohn's disease (CD), and
which has potential utility for a broad range of immune and
inflammatory conditions. Arena is also evaluating olorinab (APD371)
in a Phase 2 study for the treatment of visceral pain associated
with Crohn's disease, as well as other drug candidates in earlier
research and development stages.
In addition, Arena has several collaborations including Everest
Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "believe," "may," "potentially,"
"expect," "focused on," "potential," or words of similar meaning,
or they may be identified by the fact that they do not relate
strictly to historical or current facts. Such forward-looking
statements include, without limitation, statements about the
following: the potential of olorinab, including with respect to its
efficacy, side effects, and risks; the availability of topline
Phase 2 data for olorinab; and Arena's focus, goals, strategy,
proprietary pipeline and collaborations. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include, but
are not limited to, the following: we may need additional funds to
advance all of our programs, and you and others may not agree with
the manner we allocate our resources; risks related to developing
and commercializing drugs; enrolling patients in our ongoing and
intended clinical trials is competitive and challenging; clinical
programs may not proceed at the time or in the manner expected or
at all; the timing and outcome of research, development and
regulatory review is uncertain, and our drug candidates may not
advance in development or be approved for marketing; risks and
uncertainties relating to cash and revenues that may be generated
from product sales or other sources, including the impact of
competition; Arena's revenues are based in part on estimates,
judgment and accounting policies, and inaccuracies or disagreement
on these subjects may result in changes to Arena's guidance or
previously reported results; risks related to unexpected or
unfavorable new data; nonclinical and clinical data is voluminous
and detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; results of clinical trials and other studies are
subject to different interpretations and may not be predictive of
future results; topline data may not accurately reflect the
complete results of a particular study or trial; satisfactory
resolution of litigation or other disagreements with others;
government and third-party payor actions, including relating to
reimbursement and pricing; risks related to relying on
collaborative arrangements; the entry into or modification or
termination of collaborative arrangements; and Arena's and third
parties' intellectual property rights. Additional factors that
could cause actual results to differ materially from those stated
or implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission (SEC),
including but not limited to our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2018,
which was filed with the SEC on August 7,
2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presents-preclinical-data-for-olorinab-at-international-association-for-the-study-of-pain-world-congress-300713234.html
SOURCE Arena Pharmaceuticals, Inc.